Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Prevention of injury by resveratrol in a rat model of adenine-induced chronic kidney disease

Xiaoyan Zhang¹, Zhenning Yang², Leifang Li¹, Yanhong Qiao¹, Haiyan Jiao¹, Congxiu Miao³

¹Department of Nephrology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi 046000; ²Clinical Medicine, Norman Bethune Health Science Center of Jilin University, Changchun, Jinin 130022; ³Scientific Research Department, Changzhi Medical College, Changzhi, Shanxi 046000, China.

For correspondence:- Congxiu Miao Email: congxiumiao1392@yahoo.com Tel:+863553033016

Received: 9 April 2017 Accepted: 17 July 2017 Published: 31 August 2017

Citation: Zhang X, Yang Z, Li L, Qiao Y, Jiao H, Miao C. Prevention of injury by resveratrol in a rat model of adenine-induced chronic kidney disease. Trop J Pharm Res 2017; 16(8):2027-2032 doi: 10.4314/tjpr.v16i8.37

© 2017 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the preventive effect of resveratrol against renal pathological changes in a rat model of chronic kidney disease (CKD).

Methods: CKD was induced by daily intragastric administration of adenine (200 mg/kg) for 1 month. The effect of 10, 15, and 20 mg/kg doses of resveratrol on the levels of parathyroid hormone, phosphorous, and fibroblast growth factor-23 (FGF-23) in rat urine samples after 2 months of adenine administration were analyzed using an auto-analyzer.

Results: Resveratrol treatment significantly inhibited the adenine-mediated increase in serum parathyroid hormone, phosphorous and FGF-23 levels (p < 0.002). In rats treated with 10, 15 and 20 mg/kg doses of resveratrol after adenine, urine protein/creatinine ratio was reduced to 5, 675.6 ± 2453.7, 4, 789.8 ± 1,534.9, and 1, 965 ± 576.8 mg/g, respectively. In the untreated and normal control groups, the respective values were 7, 004 ± 1, 653.3 and 1, 627.5 ± 568.7 mg/g. Treatment with resveratrol after administration of adenine inhibited increases in creatinine, blood urea nitrogen, and uric acid levels in a dose-dependent manner (p < 0.002). Resveratrol treatment also inhibited adenine-mediated increases in monocytes and inflammatory cells. Furthermore, resveratrol prevented renal tubule swelling and expansion induced by adenine administration.

Conclusion: Resveratrol treatment prevent the renal pathological changes induced by adenine administration in a rat model of CKD by inhibiting FGF-23, parathyroid hormone, and phosphate. Thus, resveratrol may be of therapeutic importance for the treatment of CKD.

Keywords: Parathyroid hormone, Phosphate, Creatinine, Monocytes, Chronic kidney disease, Fibroblast growth factor-23